Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Leukemia, Biphenotypic, Acute 2Esophageal Neoplasms 2Burkitt Lymphoma 2Adenocarcinoma Of Esophagus 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1

Interventions

Fluorouracil 14Nivolumab 13Oxaliplatin 12Leucovorin 11Paclitaxel 7Capecitabine 7pembrolizumab 6Radiotherapy 5Cisplatin 5Taxes 4Specimen Handling 4Radiation 4Irinotecan 4Drug Therapy 4dehydroftorafur 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2futibatinib 2Levoleucovorin 2Endoscopy, Digestive System 2Endoscopy 2Carboplatin 2Biopsy 2zolbetuximab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Levoleucovorin × 90 days × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡